MAP2K7 and neoplasm: Similar to other tumor entities, MEK inhibition by cobimetinib increased ERK5 activation in at least a fraction of NSCLC cell lines, and a combination of cobimetinib and ERK5 shRNA led to a decreased tumor volume in xenotransplantation experiments [125].